Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer

Oncogene volume 29, pages 3313–3323 (2010)Cite this article

Subjects

Abstract

Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor κB, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factorβ, toll-like receptor and the IL-1 receptor inhibitor TIR8/SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050–1059.

    Article  CAS  PubMed  Google Scholar 

  • Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR . (2004). Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23: 1902–1910.

    CAS  PubMed  Google Scholar 

  • Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S et al. (2000). Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583–588.

    CAS  PubMed  Google Scholar 

  • Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR . (2000). Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629–4637.

    CAS  PubMed  Google Scholar 

  • Balkwill F . (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25: 409–416.

    CAS  PubMed  Google Scholar 

  • Balkwill F . (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361–371.

    CAS  PubMed  Google Scholar 

  • Balkwill F, Charles KA, Mantovani A . (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211–217.

    Article  CAS  PubMed  Google Scholar 

  • Balkwill F, Mantovani A . (2001). Inflammation and cancer: back to Virchow? Lancet 357: 539–545.

    CAS  PubMed  Google Scholar 

  • Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J et al. (2009). Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617–1625.

    CAS  PubMed  Google Scholar 

  • Becker C, Fantini MC, Neurath MF . (2006). TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 17: 97–106.

    CAS  PubMed  Google Scholar 

  • Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491–501.

    CAS  PubMed  Google Scholar 

  • Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98: 1010–1020.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bernstein CN, Blanchard JF, Kliewer E, Wajda A . (2001). Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854–862.

    CAS  PubMed  Google Scholar 

  • Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.

    CAS  PubMed  Google Scholar 

  • Biancone L, Petruzziello C, Calabrese E, Zorzi F, Naccarato P, Onali S et al. (2009). Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis? Gut 58: 1703.

    CAS  PubMed  Google Scholar 

  • Bollrath J, Greten FR . (2009). IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10: 1314–1319.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bollrath J, Phesse TJ, von BV, Putoczki T, Bennecke M, Bateman T et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91–102.

    CAS  PubMed  Google Scholar 

  • Bonecchi R, Locati M, Galliera E, Vulcano M, Sironi M, Fra AM et al. (2004). Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol 172: 4972–4976.

    CAS  PubMed  Google Scholar 

  • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V . (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285.

    CAS  PubMed  Google Scholar 

  • Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ . (2006). Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27: 2371–2382.

    CAS  PubMed  Google Scholar 

  • Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O′Neill LA et al. (2004). ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5: 373–379.

    CAS  PubMed  Google Scholar 

  • Burstein E, Fearon ER . (2008). Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest 118: 464–467.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Cario E, Podolsky DK . (2000). Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68: 7010–7017.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Choi PM, Zelig MP . (1994). Similarity of colorectal cancer in Crohn′s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35: 950–954.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chung YC, Chang YF . (2003). Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222–226.

    PubMed  Google Scholar 

  • Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A . (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073–1081.

    CAS  PubMed  Google Scholar 

  • Coussens LM, Werb Z . (2002). Inflammation and cancer. Nature 420: 860–867.

    CAS  PubMed  PubMed Central  Google Scholar 

  • D'Amico G, Frascaroli G, Bianchi G, Transidico P, Doni A, Vecchi A et al. (2000). Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat Immunol 1: 387–391.

    CAS  PubMed  Google Scholar 

  • Deng L, Zhou JF, Sellers RS, Li JF, Nguyen AV, Wang Y et al. (2010). A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol 176: 952–967.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eaden JA, Abrams KR, Mayberry JF . (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526–535.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN . (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188.

    CAS  PubMed  Google Scholar 

  • Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ et al. (1999). Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274: 26448–26453.

    CAS  PubMed  Google Scholar 

  • Fantini MC, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C et al. (2009). Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 136: 1308–1303.

    CAS  PubMed  Google Scholar 

  • Fukata M, Abreu MT . (2008). Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27: 234–243.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S et al. (2007). Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133: 1869–1881.

    CAS  PubMed  Google Scholar 

  • Garlanda C, Anders HJ, Mantovani A . (2009). TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 30: 439–446.

    CAS  PubMed  Google Scholar 

  • Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De BM et al. (2004). Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 101: 3522–3526.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E et al. (2007). Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 67: 6017–6021.

    CAS  PubMed  Google Scholar 

  • Garrett WS, Punit S, Gallini CA, Michaud M, Zhang D, Sigrist KS et al. (2009). Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16: 208–219.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gasche C . (2004). Review article: the chemoprevention of colorectal carcinoma. Aliment Pharmacol Ther 20 (Suppl 4): 31–35.

    CAS  PubMed  Google Scholar 

  • Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F et al. (2009). Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033–2045.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285–296.

    CAS  PubMed  Google Scholar 

  • Greten FR, Karin M . (2004). The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 206: 193–199.

    CAS  PubMed  Google Scholar 

  • Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103–113.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN . (1982). Mortality in ulcerative colitis. Gastroenterology 83: 36–43.

    CAS  PubMed  Google Scholar 

  • Herschman HR, Xie W, Reddy S . (1995). Inflammation, reproduction, cancer and all that. The regulation and role of the inducible prostaglandin synthase. Bioessays 17: 1031–1037.

    CAS  PubMed  Google Scholar 

  • Hoebe K, Janssen E, Beutler B . (2004). The interface between innate and adaptive immunity. Nat Immunol 5: 971–974.

    CAS  PubMed  Google Scholar 

  • Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65: 5009–5014.

    CAS  PubMed  Google Scholar 

  • Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N et al. (2001). Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705–714.

    CAS  PubMed  Google Scholar 

  • Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA . (2000). The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040–5044.

    CAS  PubMed  Google Scholar 

  • Jones SA . (2005). Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463–3468.

    CAS  PubMed  Google Scholar 

  • Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M et al. (2005). Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 25: 709–713.

    CAS  PubMed  Google Scholar 

  • Karin M . (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431–436.

    CAS  PubMed  Google Scholar 

  • Kelvin DJ, Michiel DF, Johnston JA, Lloyd AR, Sprenger H, Oppenheim JJ et al. (1993). Chemokines and serpentines: the molecular biology of chemokine receptors. J Leukoc Biol 54: 604–612.

    CAS  PubMed  Google Scholar 

  • Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W . (1993). Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274.

    CAS  PubMed  Google Scholar 

  • Kundu JK, Surh YJ . (2008). Inflammation: gearing the journey to cancer. Mutat Res 659: 15–30.

    CAS  PubMed  Google Scholar 

  • Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F et al. (2009). CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10: 877–884.

    CAS  PubMed  Google Scholar 

  • Li G, Yang T, Yan J . (2002). Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299: 886–890.

    CAS  PubMed  Google Scholar 

  • Li Y, de HC, Chen M, Deuring J, Gerrits MM, Smits R et al. (2010). Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59: 227–235.

    PubMed  Google Scholar 

  • Luster AD . (1998). Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436–445.

    CAS  PubMed  Google Scholar 

  • Mangan PR, Harrington LE, O′Quinn DB, Helms WS, Bullard DC, Elson CO et al. (2006). Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231–234.

    CAS  PubMed  Google Scholar 

  • Mantovani A . (1999). The chemokine system: redundancy for robust outputs. Immunol Today 20: 254–257.

    CAS  PubMed  Google Scholar 

  • Mantovani A . (2009). Cancer: inflaming metastasis. Nature 457: 36–37.

    CAS  PubMed  Google Scholar 

  • Mantovani A, Allavena P, Sica A, Balkwill F . (2008). Cancer-related inflammation. Nature 454: 436–444.

    CAS  PubMed  Google Scholar 

  • Mantovani A, Bonecchi R, Locati M . (2006). Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol 6: 907–918.

    CAS  PubMed  Google Scholar 

  • Mantovani A, Locati M, Polentarutti N, Vecchi A, Garlanda C . (2004). Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. J Leukoc Biol 75: 738–742.

    CAS  PubMed  Google Scholar 

  • Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P . (2001). Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 22: 328–336.

    CAS  PubMed  Google Scholar 

  • Mantovani A, Sica A, Locati M . (2005). Macrophage polarization comes of age. Immunity 23: 344–346.

    CAS  PubMed  Google Scholar 

  • Martinez de la Torre Y, Buracchi C, Borroni EM, Dupor J, Bonecchi R, Nebuloni M et al. (2007). Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 104: 2319–2324.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ . (1989). Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169: 1485–1490.

    CAS  PubMed  Google Scholar 

  • Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA . (2004). The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 10: 352–356.

    PubMed  Google Scholar 

  • Mazzucchelli L, Hauser C, Zgraggen K, Wagner HE, Hess MW, Laissue JA et al. (1996). Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol 178: 201–206.

    CAS  PubMed  Google Scholar 

  • McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS et al. (2003). Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 112: 598–607.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5: 828–831.

    CAS  PubMed  Google Scholar 

  • Murphy PM . (1994). The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593–633.

    CAS  PubMed  Google Scholar 

  • Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K et al. (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145–176.

    CAS  PubMed  Google Scholar 

  • Nakamura K, Honda K, Mizutani T, Akiho H, Harada N . (2006). Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 12: 4628–4635.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Naugler WE, Karin M . (2008). NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD et al. (2007). The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 117: 1884–1892.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD et al. (2001). The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 158: 867–877.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nibbs RJ, Wylie SM, Yang J, Landau NR, Graham GJ . (1997). Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem 272: 32078–32083.

    CAS  PubMed  Google Scholar 

  • Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN . (1994). Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 29: 425–429.

    CAS  PubMed  Google Scholar 

  • Noguchi M, Hiwatashi N, Liu Z, Toyota T . (1998). Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 43: 203–209.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R . (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694–702.

    CAS  PubMed  Google Scholar 

  • Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S . (1996). Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39: 87–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T . (2002). Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 17: 1078–1083.

    PubMed  Google Scholar 

  • Osawa E, Nakajima A, Fujisawa T, Kawamura YI, Toyama-Sorimachi N, Nakagama H et al. (2006). Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer 118: 2232–2236.

    CAS  PubMed  Google Scholar 

  • Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E et al. (2001). Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61: 1733–1740.

    CAS  PubMed  Google Scholar 

  • Pasparakis M . (2008). IKK/NF-kappaB signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunol 1 (Suppl 1): S54–S57.

    CAS  PubMed  Google Scholar 

  • Peskar BM, Dreyling KW, May B, Schaarschmidt K, Goebell H . (1987). Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 32: 51S–56S.

    CAS  PubMed  Google Scholar 

  • Polentarutti N, Rol GP, Muzio M, Bosisio D, Camnasio M, Riva F et al. (2003). Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 14: 211–218.

    CAS  PubMed  Google Scholar 

  • Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560–570.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T et al. (2009). Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69: 7884–7892.

    CAS  PubMed  Google Scholar 

  • Rakoff-Nahoum S, Medzhitov R . (2007). Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317: 124–127.

    CAS  PubMed  Google Scholar 

  • Rakoff-Nahoum S, Medzhitov R . (2009). Toll-like receptors and cancer. Nat Rev Cancer 9: 57–63.

    CAS  PubMed  Google Scholar 

  • Reinecker HC, Loh EY, Ringler DJ, Mehta A, Rombeau JL, MacDermott RP . (1995). Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 108: 40–50.

    CAS  PubMed  Google Scholar 

  • Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK . (2007). Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26: 4833–4841.

    CAS  PubMed  Google Scholar 

  • Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R . (2008). Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 204: 511–524.

    CAS  PubMed  Google Scholar 

  • Rollins BJ . (1997). Chemokines. Blood 90: 909–928.

    CAS  PubMed  Google Scholar 

  • Sinicrope FA, Gill S . (2004). Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23: 63–75.

    CAS  PubMed  Google Scholar 

  • Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC et al. (2008a). Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75: 668–676.

    CAS  PubMed  Google Scholar 

  • Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G . (2008b). Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 14: 4434–4439.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA . (2002). Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62: 6323–6328.

    CAS  PubMed  Google Scholar 

  • Szlosarek P, Charles KA, Balkwill FR . (2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42: 745–750.

    CAS  PubMed  Google Scholar 

  • Szlosarek PW, Balkwill FR . (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4: 565–573.

    CAS  PubMed  Google Scholar 

  • Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. (2010). Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482–491.

    CAS  PubMed  Google Scholar 

  • Thomassen E, Renshaw BR, Sims JE . (1999). Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11: 389–399.

    CAS  PubMed  Google Scholar 

  • Tsujii M, DuBois RN . (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493–501.

    CAS  PubMed  Google Scholar 

  • Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M et al. (1999). Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155: 331–336.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C et al. (2009). The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut. 59: 197–206.

    PubMed  Google Scholar 

  • Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L et al. (2003). SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 4: 920–927.

    CAS  PubMed  Google Scholar 

  • Waldner M, Schimanski CC, Neurath MF . (2006). Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol 12: 7233–7238.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wang H, Czura C, Tracey K . (2003). The Cytokine Handbook In: Thomson A. and Lotze M. (eds). Elsevier Science: London, pp 837–860.

    Google Scholar 

  • Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D et al. (2007). The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26: 461–475.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the Broad Medical Research Program, the Italian Ministery of Health (Ricerca Finalizzata 2006, n.72 and Bando Giovani Ricercatori), Fondazione Cariplo and the Italian Association for Cancer Research (My first AIRC Grant) to SD, and the European Community (INNOCHEM project 518167), the Ministero dell’Istruzione dell’Università e della Ricerca (Rome, Italy; PRIN project 2002061255; FIRB project RBIN04EKCX) and Fondazione Cariplo (Milan, Italy; NOBEL project). This work was conducted in the context and with the support of the Fondazione Humanitas per la Ricerca (Rozzano, Italy).

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Inflammatory Bowel Disease Unit, Milan, Italy

    S Danese

  2. Laboratory of Inflammation and Immunology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy

    A Mantovani

Authors
  1. S Danese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to S Danese or A Mantovani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Danese, S., Mantovani, A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer. Oncogene 29, 3313–3323 (2010). https://doi.org/10.1038/onc.2010.109

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.109

Keywords

This article is cited by

Search

Advanced search

Quick links